bioRxiv Science⌕ Search

Biology subjects

Riccardi Sirtori, F.

Publications and source records attributed to Riccardi Sirtori, F..

2 recordsLinked to original sources

Evaluating Cross-linking-driven integrative modeling in peptide-HLAII complexes prediction with insights for refining predictive accuracy

ABSTRACTIn silico prediction of peptide-HLAII (human leucocyte antigen class II) complexes has emerged as a crucial approach in bioinformatics for deciphering antigen presentation mechanisms. Several in silico tools have been developed to predict peptide binding to HLAII alleles, trying to deconvolute the intricate peptide-HLAII binding specificity. These approaches integrate bases from molecular modeling, machine learning, and bioinformatics to predict peptide-HLAII interactions. Initially, structure-based methods relying on molecular docking algorithms were widespread, utilizing structural data of HLAII molecules and peptides to infer plausible binding conformations. These methods often faced challenges in accuracy due to the dynamic nature of peptide-HLAII interactions. Besides, the high flexibility of peptide sidechains makes their placement into the HLA-binding site even more complex. In recent years, machine learning techniques have drawn attention to peptide-HLAII binding predictions. Supervised learning algorithms, such as support vector machines (SVMs), neural networks, and ensemble methods, have been considerably applied to discriminate patterns from large datasets of experimentally validated peptide-HLAII binding affinities (like Immune Epitope Data Base, IEDB) and more recently mass spectrometry- eluted ligands from MHC-associated peptide proteomics (MAPPs) assay. The role of experiment- assisted integrative modeling in aiding peptide-HLAII complexes prediction still needs to be clarified. In this work, we benchmarked the use of AlphaLink2 (AlphaFold2 + cross-links restraints) and compared it to AlphaFold2 Multimer in predicting correct peptide binding motifs. These results can pave the way to an integrated strategy for vaccine development and protein deimmunization or autoimmunity mitigation.

immunology↗

PROxAb Shuttle: A non-covalent plug-and-play platform for the rapid generation of tumor-targeting antibody-PROTAC conjugates

Proteolysis-targeting chimeras (PROTACs) have evolved in recent years from an academic idea to a therapeutic modality with more than 25 active clinical programs. However, achieving oral bioavailability and cell-type specificity remains a challenge, especially for PROTACs recruiting the von Hippel-Lindau (VHL) E3 ligase. Herein, we present an unprecedented, plug- and-play platform for VHL-recruiting PROTACs to overcome these limitations. Our platform allows for the generation of non-covalent antibody-PROTAC complexes within minutes and obviates the need for prior PROTAC modification, antibody-drug linker chemistry optimization or bioconjugation. Our technology relies on camelid-derived antibody domains (VHHs) which can easily be engineered into existing therapeutic antibody scaffolds. The resulting targeted, bispecific fusion proteins can be complexed with PROTACs at defined PROTAC-to-antibody ratios and have been termed PROxAb Shuttles. PROxAb Shuttles can prolong the half-life of PROTACs from hours to days, demonstrate anti-tumor efficacy in vivo and have the potential for reloading in vivo to further boost efficacy.

biochemistry↗